Experimental infection with Mycobacterium avium, serotype 2, in pigs. 1. Intravenous inoculations

A porcine strain of Mycobacterium avium, Serotype 2, was used for intravenous inoculation of pigs in doses 5, 1, 10⁻¹, 10⁻² and 10⁻³ mg (1 mg = 78 × 10⁶ viable units), 2 pigs per dose.Dose 5 mg proved fatal for both of the inoculated pigs, which were killed in extremis 64 and 69 days, respectively, after inoculation. Dose 1 mg caused clinical disease in 1 of 2 pigs, but was not lethal. Post mortem, the clinically affected pigs showed a generalized granulomatous tuberculosis. The other pig given 1 mg and the pigs given smaller doses, showed no clinical signs, and lesions and presence of acid-fasts were mostly limited to the lymph nodes of the lung, liver and digestive tract.All the pigs showed delayed hypersensitivity to avian PPD tuberculin (1000 t.u.) and some of them cross-reacted with human PPD tuberculin (1000 t.u.). The clinically affected pigs gave a very weak response to tuberculin, the others a strong response.The smallest dose capable of establishing an infection and producing tuberculous lesions was not determined, but seems to be less than 10⁻³ mg (78000 viable organisms).     

Minimum infusion rate and hemodynamic effects of propofol, propofol-lidocaine and propofol-lidocaine-ketamine in dogs

ObjectiveTo evaluate the effects of a constant rate infusion (CRI) of lidocaine alone or in combination with ketamine on the minimum infusion rate (MIR) of propofol in dogs and to compare the hemodynamic effects produced by propofol, propofol-lidocaine or propofol-lidocaine-ketamine anesthesia.Study designProspective, randomized cross-over experimental design.AnimalsFourteen adult mixed-breed dogs weighing 15.8 ± 3.5 kg.MethodsEight dogs were anesthetized on different occasions to determine the MIR of propofol alone and propofol in combination with lidocaine (loading dose [LD] 1.5 mg kg^?1, CRI 0.25 mg kg^?1 minute^?1) or lidocaine (LD 1.5 mg kg^?1, CRI 0.25 mg kg^?1 minute^?1) and ketamine (LD 1 mg kg^?1, CRI 0.1 mg kg^?1 minute^?1). In six other dogs, the hemodynamic effects and bispectral index (BIS) were investigated. Each animal received each treatment (propofol, propofol-lidocaine or propofol-lidocaine-ketamine) on the basis of the MIR of propofol determined in the first set of experiments.ResultsMean ± SD MIR of propofol was 0.51 ± 0.08 mg kg^?1 minute^?1. Lidocaine-ketamine significantly decreased the MIR of propofol to 0.31 ± 0.07 mg kg^?1 minute^?1 (37 ± 18% reduction), although lidocaine alone did not (0.42 ± 0.08 mg kg^?1 minute^?1, 18 ± 7% reduction). Hemodynamic effects were similar in all treatments. Compared with the conscious state, in all treatments, heart rate, cardiac index, mean arterial blood pressure, stroke index and oxygen delivery index decreased significantly, whereas systemic vascular resistance index increased. Stroke index was lower in dogs treated with propofol-lidocaine-ketamine at 30 minutes compared with propofol alone. The BIS was lower during anesthesia with propofol-lidocaine-ketamine compared to propofol alone.Conclusions and clinical relevanceLidocaine-ketamine, but not lidocaine alone, reduced the MIR of propofol in dogs. Neither lidocaine nor lidocaine in combination with ketamine attenuated cardiovascular depression produced by a continuous rate infusion of propofol.     

桥接治疗急性缺血性脑卒中患者的血管再通率及远期神经功能恢复分析

目的 探讨重组组织型纤溶酶原激活物（rtPA）静脉溶栓联合血管内介入治疗（即桥接治疗法）对急性缺血性脑卒中患者的治疗效果。方法 选取我院（2015年1月-2018年1月）收治的100例急性缺血性脑卒中患者进行回顾性分析,根据治疗方法分为观察组47例（桥接治疗法）、对照组53例（rtPA静脉溶栓疗法）,对比两组治疗后的血管再通率、神经功能恢复情况。结果 观察组前循环梗死血管（颈内动脉、大脑前动脉、大脑中动脉）再通率91.49%,对照组前循环梗死血管再通率50.94%,两组比较差异具有统计学意义（P<0.01）;观察组治疗14 d、治疗28 d、治疗3个月,神经功能缺损（NIHSS）评分均显著的低于对照组（P<0.01）;根据mRS标准,观察组的预后良好87.23%,对照组预后良好52.83%,两组比较差异具有统计学意义（P<0.01）;观察组的并发症发生率8.51%,对照组并发症发生率16.98%,两组比较差异无统计学意义（P>0.05）。结论 桥接治疗对缺血性脑卒中患者的效果优于rtPA静脉溶栓疗法,对于患者远期神经功能恢复具有显著效果。     

Pharmacokinetics of thymoquinone in layer chickens following oral and intravenous administration

Thymoquinone (TQ) is the major constituent of Nigella sativa and known to possess a variety of pharmacological effects. This study was designed to evaluate the pharmacokinetic profile of TQ following oral (PO) and intravenous (IV) administration in layer chickens. The layer chickens were equally divided into two groups (six chickens in each group, total 12 chickens), and TQ was administered via PO and IV routes. For PO route, the dose was 20 mg/kg b.w. and for IV route, 5 mg/kg b.w. was administered, respectively. A sensitive and accurate High‐Performance Liquid Chromatography (HPLC) technique was validated for the quantification of TQ from plasma. The limit of detection (LOD) and limit of quantification (LOQ) were 0.02 µg/ml and 0.05 µg/ml, respectively with >80% recovery. Maximum plasma concentration (C_max) following PO and IV administration was 8.805 and 4.497 µg/ml, respectively, while time to reach at maximum concentration (T_max) was 1 and 0.1 hr, respectively. The elimination half‐lives were recorded as 1.02 and 0.978 hr, whereas the mean residence times were 1.79 and 1.036 hr following both PO and IV administration, respectively. The 85% PO bioavailability was indicative that TQ could be used for various therapeutic purposes in layer chickens.     

Pharmacokinetics of levosulpiride after single‐dose administration in goats (Capra hircus) by different routes of administration

Levosulpiride (LSP) is the l‐enantiomer of sulpiride, and LSP recently replacing sulpiride in several EU countries. Several studies about LSP in humans are present in the literature, but neither pharmacodynamic nor pharmacokinetic data of LSP is present for veterinary species. The aim of this study was to assess the pharmacokinetic profile of LSP after intravenous (IV), intramuscular (IM), and oral (PO) administration in goats. Animals (n = 6) were treated with 50 mg LSP by IV, IM, and PO routes according to a randomized cross‐over design (3 × 3 Latin‐square). Blood samples were collected prior and up to 24 hr after LSP administration and quantified using a validated HPLC method with fluorescence detection. IV and IM administration gave similar concentration versus time curve profiles. The IM mean bioavailability was 66.97%. After PO administration, the drug plasma concentrations were detectable only in the time range 1.5–4 hr, and the bioavailability (4.73%) was low. When the AUC was related to the administered dose in mg/kg, there was a good correlation in the IV and IM groups, but very low correlation for the PO route. In conclusion, the IM and IV administrations result in very similar plasma concentrations. Oral dosing of LSP in goats is probably not viable as its oral bioavailability was very low.     

The clinical efficacy of EMLA cream for intravenous catheter placement in client-owned dogs

Objective

To assess the reaction of client-owned dogs to intravenous (IV) catheter placement after applying a local anaesthetic (EMLA) or placebo cream for either 30 or 60 minutes.

INTRAVENOUS ALFAXALONE ANAESTHESIA IN LEOPARD GECKOS (EUBLEPHARIS MACULARIUS)

Intravenous alfaxalone, administered at a dose of 5 mg/kg in the jugular vein, was evaluated in 20 leopard geckos (Eublepharis macularius) to ascertain its ability to provide anesthesia. The induction time, time to loss of mandibular tone, interval of deep anesthesia, and full recovery time were 27.5 ± 30.7 seconds (10 to 56 seconds), 1.3 ± 1.4 minutes (11 seconds to 4 minutes), 12.5 ± 2.2 minutes (11.11 to 15.39 minutes), and 18.8 ± 12.1 minutes (10.4 to 52.31 minutes), respectively. A significant reduction in heart rate (74 ± 12.9 beats/minute) was recorded between 2 and 24 minutes after alfaxalone administration. A significant decrease in respiratory rate (26.8 ± 10.1 breaths/minute) was recorded 2 minutes after alfaxalone administration, and respiratory rate remained lower than the basal rate (31.4 ± 3.1 breaths/minute) for 24 minutes but without statistical significance. The intravenous administration of alfaxalone in leopard geckos achieved a rapid onset of anesthesia and a suitable recovery time. Based on this investigation, an afaxalone dose of 5 mg/kg intravenously proved to be suitable for sedation before tracheal intubation. Moreover, the administration route via the jugular vein, was acceptable in leopard geckos; a species in which other venipuncture sites can be challenging or inaccessible.     

静脉注射不同锌源与锌水平对肉仔鸡生长性能及组织锌含量的影响

用378只22日龄商品代AA肉公鸡进行静脉注射试验,研究不同锌源与锌水平对肉仔鸡生长性能及组织锌含量的影响。采用4种锌源（ZnSO₄·7H₂O、弱络合强度Zn-AA C、中等络合强度Zn-Pro B和偏极强络合强度Zn-Pro A）与3个日粮锌吸收率（0%、6％和12％）静脉注射锌水平构成的4×3两因子安排的完全随机设计,将22日龄肉公鸡按体重随机分成9个组(每组7个重复笼,每个重复笼6只鸡),分别翅静脉注射生理盐水（对照组）,或在生理盐水中溶解硫酸锌及弱、中等和偏极强络合强度有机锌源的注射液12 d。结果表明,锌源显著影响（P<0.10）注射后6 d胫骨灰锌含量,但对肉仔鸡注射后1～6 d和7～12 d的日采食量、日增重、料重比、第6 天胰脏锌及第12 天胰脏锌和胫骨灰锌均无显著影响（P>0.10）;锌水平显著影响（P<0.10）肉仔鸡注射后1～6 d的日增重和料重比、第6和12天的胰脏锌和胫骨灰锌,而对肉仔鸡注射后1～6 d日采食量和7～12 d的日采食量、日增重和料重比均无显著影响（P>0.10）;锌源与锌水平互作对肉仔鸡注射后以上各观测指标均无显著影响（P>0.10）。偏极强络合强度有机锌源组鸡胫骨灰锌含量显著低于弱络合强度有机锌源组和中等络合强度有机锌源组（P<0.10）,且有低于无机硫酸锌组的趋势（P>0.10）。对照组肉仔鸡的日增重显著低于注射锌吸收率6%组（P<0.10）,其料重比显著高于注射锌吸收率6%与12%组（P<0.10）,其它锌吸收率注射水平组之间鸡的日增与重料重比均无显著差异（P>0.10）;随着注射锌水平的升高,肉仔鸡注射后第6、12天胰脏和胫骨灰锌含量呈线性升高（P<0.10）。本试验结果表明,相对于胰脏锌和生长性能而言,静脉注射后第6天的胫骨灰锌能更敏感地反映出不同锌源对肉仔鸡生物学利用性的差异,而偏极强络合强度的有机锌最不利于肉仔鸡体组织的利用。